Regeneron Pharmaceuticals (REGN) Earnings Date, Estimates & Call Transcripts

$1,037.03

-9.88 (-0.94%)

(As of 10:00 AM ET)

Upcoming Earnings Date: Oct. 31
Before Market Opens
Confirmed
Actual EPS (Aug. 1): $11.56 Beat By $2.63
Consensus EPS (Aug. 1): $8.93

REGN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

REGN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ad Crypto 101 Media

[Urgent!] Web3 Could Send One Crypto Soaring

Venture Capital corporations and blockchain funds are pouring money into Web3 gaming. And there's one little-known crypto coin that's poised for RAPID growth as we see Web3 expand over the next few years.

Click here to review my research and unique strategy to score potential profits from this under-the-

Regeneron Pharmaceuticals Analyst EPS Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2024	2	$7.48	$8.05	$7.77
Q2 2024	2	$9.20	$9.67	$9.44
Q3 2024	2	$9.80	$11.42	$10.61
Q4 2024	2	$7.72	$10.57	$9.15
FY 2024	8	$34.20	$39.71	$36.96

REGN Earnings Date and Information

Regeneron Pharmaceuticals last posted its earnings results on August 1st, 2024. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The firm earned $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Its revenue for the quarter was up 12.3% on a year-over-year basis. Regeneron Pharmaceuticals has generated $33.85 earnings per share over the last year ($33.85 diluted earnings per share) and currently has a price-to-earnings ratio of 30.9. Earnings for Regeneron Pharmaceuticals are expected to grow by 7.33% in the coming year, from $37.80 to $40.57 per share. Regeneron Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Thursday, October 31st, 2024. Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, October 31st at 8:30 AM Eastern. Interested parties can register for or listen to the call..

Regeneron Pharmaceuticals Earnings History by Quarter

Time Frame

Start Date

End Date

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
10/31/2024 (Confirmed)	-	-	-	-	-	-	-
8/1/2024	Q2 2024	$8.93	$11.56	+$2.63	$7.79	$3.38 billion	$3.55 billion
5/2/2024	Q1 2024	$8.46	$7.97	($0.49)	$9.67	$3.19 billion	$3.15 billion
2/2/2024	Q4 2023	$10.73	$11.86	+$1.13	$10.17	$3.29 billion	$3.43 billion
11/2/2023	Q3 2023	$9.39	$10.17	+$0.78	$11.45	$3.23 billion	$3.36 billion
8/3/2023	Q2 2023	$8.48	$10.24	+$1.76	$9.08	$3.02 billion	$3.16 billion
5/4/2023	Q1 2023	$7.71	$8.44	+$0.73	$9.71	$2.92 billion	$3.16 billion
The trade we can’t talk about over email (Ad) There is a red-hot sector right now that it seems like Google doesn’t want us to talk about… Because when we talk about it in email, sometimes those messages have trouble making it through to you. And it’s not just email! Videos from Youtube are also being removed. We don’t know exactly why it’s happening… Or if it’s being done manually or by an algorithm…. But we do know that you probably are going to want to see what they’re censoring. Decide for yourself when you get the full details here.
2/3/2023	Q4 2022	$8.18	$12.56	+$4.38	$11.42	$3.11 billion	$3.41 billion
11/3/2022	Q3 2022	$8.55	$9.98	+$1.43	$8.30	$2.79 billion	$2.94 billion
8/3/2022	Q2 2022	$8.53	$9.77	+$1.24	$12.07	$2.80 billion	$2.86 billion
5/4/2022	Q1 2022	$9.37	$11.49	+$2.12	$14.37	$2.69 billion	$2.97 billion
2/4/2022	Q4 2021	$18.49	$23.72	+$5.23	$27.75	$4.49 billion	$4.95 billion
11/4/2021	Q3 2021	$9.81	$15.37	+$5.56	$16.41	$2.80 billion	$3.45 billion
8/5/2021	Q2 2021	$8.81	$25.80	+$16.99	$27.97	$3.90 billion	$5.14 billion
5/6/2021	Q1 2021	$7.78	$9.89	+$2.11	$10.09	$2.69 billion	$2.53 billion
2/4/2021	Q4 2020	$7.11	$9.53	+$2.42	$7.20	$2.40 billion	$2.42 billion
11/5/2020	Q3 2020	$9.52	$8.36	($1.16)	$7.97	$2.09 billion	$2.29 billion
8/5/2020	Q2 2020	$5.59	$7.16	+$1.57	$4.97	$1.74 billion	$1.95 billion
5/5/2020	Q1 2020	$6.13	$6.60	+$0.47	$6.31	$1.81 billion	$1.83 billion
2/6/2020	Q4 2019	$6.03	$7.50	+$1.47	$6.23	$2.10 billion	$2.17 billion
11/5/2019	Q3 2019	$5.13	$6.67	+$1.54	$5.82	$1.98 billion	$2.05 billion

Regeneron Pharmaceuticals Earnings - Frequently Asked Questions

When is Regeneron Pharmaceuticals's earnings date?: Regeneron Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Thursday, October 31st, 2024. Learn more on REGN's earnings history.
Did Regeneron Pharmaceuticals beat their earnings estimates last quarter?: In the previous quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) reported $11.56 earnings per share (EPS) to beat the analysts' consensus estimate of $8.93 by $2.63. Learn more on analysts' earnings estimate vs. REGN's actual earnings.
How can I listen to Regeneron Pharmaceuticals's earnings conference call?: The conference call for Regeneron Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call
How can I read Regeneron Pharmaceuticals's conference call transcript?: The conference call transcript for Regeneron Pharmaceuticals's latest earnings report can be read online. Read Transcript
How much revenue does Regeneron Pharmaceuticals generate each year?: Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded annual revenue of $13.12 billion.
How much profit does Regeneron Pharmaceuticals generate each year?: Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded net income of $3.95 billion. REGN has generated $33.85 earnings per share over the last four quarters.
What is Regeneron Pharmaceuticals's price-to-earnings ratio?: Regeneron Pharmaceuticals (NASDAQ:REGN) has a trailing price-to-earnings ratio of 30.93 and a forward price-to-earnings ratio of 27.70. The price/earnings-to-growth ratio is 3.56.
What is Regeneron Pharmaceuticals's EPS forecast for next year?: Regeneron Pharmaceuticals's earnings are expected to grow from $37.80 per share to $40.57 per share in the next year, which is a 7.33% increase.